Nocturnal frog
Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack
Home / Health News / 2008 / March 2008 / March 3, 2008
Nocturnal frogs anti-infection substance gives new hope for diabetics

Top News

Karnataka High Court orders Ramoji Rao to appear in Ballari Court

Parrots throng a temple in Indore to eat sorgam

Baloch prefer Balochistans sovereignty than Paks, says Bugtis grandson

Love, art and music are all that matter to Peaches Geldof

Chidambaran says government to speed up reforms

Cheshire council gives Flintoff permission to build four million pound mansion

Tiny fossils take Antarctic Dry Valleys origin back to 14 million years

One cheese sandwich as fatty as 5 five pieces of deep-fried chicken!

Nocturnal frogs anti-infection substance gives new hope for diabetics

A nocturnal frog that dwells in the ponds and lagoons of the Amazon may prove to be a saviour for millions of diabetics some day.

London, March 3 : A nocturnal frog that dwells in the ponds and lagoons of the Amazon may prove to be a saviour for millions of diabetics some day.

The new hope results from the finding that the body of the South American "paradoxical frog" (Pseudis paradoxa) produces an anti-infection substance that can stimulate the release of insulin, the vital hormone that is deficient in sufferers from diabetes.

Research collaborators from the University of Ulster in Northern Ireland and United Arab Emirates University say that they have made an artificial copy of the peptide pseudin-2, which they believe may be used to boost insulin production in people with Type 2 diabetes.

The researchers say that the paradoxical frog's peptide was found to increase the release of insulin in cultured cells by 50 per cent in laboratory tests.

They believe that a synthetic version of pseudin-2 could join a new class of medicines called incretin mimetics, which help diabetics control their condition when dietary changes or other medicines have failed.

"We are at an exciting stage with this research. We have tested a more potent synthetic version of the pseudin-2 peptide and have found that it has the potential for development into a compound for the treatment of Type 2 diabetes. Now we need to take this a step further and put our work into practice to try and help people with Type 2 diabetes," Times Online quoted Yasser Abdel-Wahab, senior lecturer in biomedical sciences at the University of Ulster, as saying.

The researchers, however, concede that further research is required before the therapy is ready to be tested on human patients.

"More research is needed, but there is a growing body of work around natural anti-diabetic drug discovery that is already yielding fascinating results," Abdel-Wahab said.

Douglas Smallwood, Chief Executive of Diabetes UK, said: "We welcome this innovative research that could benefit some of the two million people in the UK with Type 2 diabetes.

He added: "Although it can be managed with diet and physical activity, Type 2 diabetes is progressive and may require tablets and/or insulin to control it effectively. Good diabetes control reduces the risk of complications including blindness, heart disease, kidney problems and amputation, so new treatments are vital."

Further details of the research will be presented at the Diabetes UK Annual Professional Conference in Glasgow.

ANI

July 24, 2008

July 23, 2008

July 22, 2008

July 21, 2008

July 20, 2008

July 19, 2008